An observational study in Food Allergy, sponsored by Nutricia Nutrition Clinique. Terminated at 2 sites in France. Open to participants aged Up to 8 Months. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational
difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Food Hypersensitivity with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Food Hypersensitivity · France.
Among the 31 studies in Food Hypersensitivity with a site in France, this one is the 13th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2024, is one of 13 observational ones, and was the 25th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →4 of the 31 studies in Food Hypersensitivity with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 5+
Lille Catholic University · Sites in France
Ages up to 16
University Hospital, Lille · Sites in France
Ages 6 mo–17 yrs
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.
This study: Up to 8 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
This study's enrollment of 21 is below the median of 149 across 120 observational studies indexed under Food Hypersensitivity.
Median enrollment 167 across the 18 interventional studies, 100 across the 13 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Nutricia Nutrition Clinique, one of the names counted as Danone. Under that name alone:
Nutricia Nutrition Clinique is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Danone has 2 studies filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
2 of the studies in Food Hypersensitivity with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06872996Centre Hospitalier Régional d'OrléansTrophallergen Prick Tests (PT) : Influence of Food Sample Shelf Life on the Reproducibility of PT Results | 2027-10-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Food Hypersensitivity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the symptoms and their evolution up to the age of 5 years in a population of newly diagnosed infants with a suspected or confirmed allergy to cow proteins, for whom the doctor prescribed the Pepticate® Syneo® replacement formula as soon as they were diagnosed.
The Pepticate® Syneo® product is an advanced protein hydrolyzate, food type intended for special medical purposes. This is a product already available on the market.
This is a prospective, observational, descriptive, longitudinal, multicentric study aimed at describing a cohort of infants with a recently suspected or confirmed allergy to cow's milk protein, who were treated in outpatient and inpatient settings.
The recruitment of patients eligible for this observatory will be done via community medicine (private practices of pediatricians and general practitioners) as well as in hospitals throughout France.
The target population of our project will be infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed, newly diagnosed cow protein allergy requiring, according to the investigator's judgement, an initial prescription of the Pepticate® Syneo® advanced cow protein hydrolysate infant formula.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed cow protein allergy.
Other: Pepticate® Syneo®
Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
Number and proportion of symptoms
Numbers and proportion of symptoms (cutaneous, gastrointestinal, respiratory...), and their evolution according to the different forms of cow protein allergy: immediate Immunoglobulin E mediated, delayed non-Immunoglobulin E mediated or mixed and acute food protein-induced enterocolitis syndrome.
Time frame: 5 years
Ran from Sep 2024 to primary completion in Sep 2024, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2024 → Sep 2024, primary completion Nov 2031 → Sep 2024 and completion Nov 2031 → Sep 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
difficulties in recruiting investigating physicians and patients, both of which are linked to the duration of recruitment (3 years), patient follow-up (5 years), the indispensable involvement of parents in filling in numerous questionnaires on a regu
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.